Skip to content
newsechoasia

newsechoasia

Press Releases, Companye Events, Business News in Asia

Menu
  • Home
  • SeaPRwire
  • ACN
  • JCN
  • EQS
  • Finance
  • Business
  • Instant
  • Contact

Tag: combination

Posted onSeptember 28, 2022

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery,…

Read More
Posted onSeptember 6, 2022

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

TOKYO, Sep 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from…

Read More
Posted onMay 27, 2022

Eisai Contributes to the Science of Cancer Medicine at ASCO 2022

TOKYO, May 27, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from…

Read More
Posted onMarch 17, 2022

Hua Medicine Announces 2021 Annual Results

SHANGHAI, CHINA, Mar 17, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of…

Read More
Posted onMarch 7, 2022

LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma

TOKYO, Mar 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine…

Read More
Posted onJanuary 31, 2022

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

TOKYO, Jan 31, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine…

Read More
Posted onJanuary 17, 2022

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

TOKYO, Jan 17, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on…

Read More
Posted onNovember 1, 2021

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

TOKYO, Nov 1, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP)…

Read More
Posted onSeptember 8, 2021

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

NEW JERSEY, the U.S. and HANGZHOU, China, Sep 8, 2021 – (ACN Newswire via SEAPRWire.com) – Adlai Nortye, a global biopharmaceutical company focused on developing…

Read More
Posted onAugust 19, 2021

Hua Medicine Announces 2020 Interim Results

SHANGHAI, CHINA, Aug 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the consolidated results of the…

Read More
Posted onAugust 12, 2021

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)

TOKYO and KENILWORTH, N.J., Aug 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD…

Read More
Posted onJuly 16, 2021

Black Spade Acquisition Co Announces Pricing of $150 Million Initial Public Offering

HONG KONG, Jul 16, 2021 – (ACN Newswire via SEAPRWire.com) – Black Spade Acquisition Co (the “Company”) today announced the pricing of its initial public…

Read More
Posted onMay 20, 2021

Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

TOKYO, May 20, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products…

Read More
Posted onMarch 31, 2021

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, N.J.,…

Read More
Posted onMarch 30, 2021

Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

TOKYO, Mar 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has…

Read More
Posted onMarch 4, 2021

APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA

FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, Mar 4, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics, Inc., an innovative biopharmaceutical company committed to the…

Read More

目录导航

  • 首页
  • SeaPRwire
  • ACN Newswire
  • JCN Newswire
  • EQS Newswire
  • 商业新闻
  • 财经新闻
  • 即时热闻
  • 联络我们
  • 关于我们
  • RSS

Singapore News

  • 哈马斯策划渗透美国支持的加沙援助点,迫使其暂时关闭 September 11, 2025
  • 值得关注的创新科技股 September 11, 2025
  • 查理·柯克因坚定支持获加沙人质家属哀悼 September 11, 2025
  • The Sixth Bosum Private Enterprise Gala Concludes Successfully, Bosum AI Agent Debuts, and Industry Leaders Set New Directions for Innovation September 11, 2025
  • Doubleview Gold Corp Announces Important High-Grade Copper and Gold Intercepts at Hat Polymetallic Deposit in Northwestern British Columbia September 11, 2025
  • 英国驻美国大使因与爱泼斯坦的关系遭解职 September 11, 2025
  • Envirosite 扩展至澳大利亚,收购 Land Insight 资产 September 11, 2025
  • The 10th Belt and Road Summit concludes successfully September 11, 2025
  • Intel的定制芯片策略 September 11, 2025
  • CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration September 11, 2025
  • 专家警告:9/11事件24年后,Al Qaeda 仍然是最危险的恐怖组织 September 11, 2025
  • Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development September 11, 2025
  • GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail’s State-of the-Art Digital Factory September 11, 2025
  • A Sparkling New Chapter: Spritzer’s First-Ever Mini-Drama Series Stars New Brand Ambassador Anna Jobling September 11, 2025
  • GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail’s State-of-the-Art Train Manufacturing Facility September 11, 2025

Links

  • YAHOO
  • NASDAQ
  • Bloomberg
  • Newswire
  • EastMud
  • AsiaEase
  • NetDace
  • PostVN
  • VOASG
  • EventPH
© Copyright 2024 – NewsEchoAsia